(Asn(4-aminobutyl)1·7·23,Gln(4-aminobutyl)3·11·22)-Amyloidβ-Protein (1-40)

CompanySerial Number：DC160025(25)

ProductName：(Asn(4-aminobutyl)1·7·23,Gln(4-aminobutyl)3·11·22)-Amyloidβ-Protein (1-40)

Synonym： (Asp(4-aminobutylamide)1·7·23,Glu(4-aminobutylamide)3·11·22)-Amyloidβ-Protein (1-40)

CASNo.：

Sequence(three-letter)：H-Asn(4-aminobutyl)-Ala-Gln(4-aminobutyl)-Phe-Arg-His-Asn(4-aminobutyl)-Ser-Gly-Tyr-Gln(4-aminobutyl)-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Gln(4-aminobutyl)-Asn(4-aminobutyl)-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-OHTrifluoroacetate salt

Sequence(one-letter)： Asn(4-aminobutyl)-A-Gln(4-aminobutyl)-FRH-Asn(4-aminobutyl)-SGY-Gln(4-aminobutyl)-VHHQKLVFFA-Gln(4-aminobutyl)-Asn(4-aminobutyl)-VGSNKGAIIGLMVGGVV-OHTrifluoroacetatesalt

ConstitutionalFormula：

MolecularFormula： C218H355N65O52S

MolecularWeight：4750.69

References： T.M.Wengenacket al., Nat. Biotechnol., 18, 868 (2000)

Illustration：Ithas been shown that the permeability of amyloid β-peptide (Aβ) at theblood-brain barrier can be increased by at least twofold through covalentmodification with the naturally occurring polyamine putrescine(1,4-diaminobutane). Following intravenous injection radiolabeled,putrescine-modified Aβ labels amyloid deposits in vivo in a transgenic mousemodel of Alzheimer's disease (AD) as well as in vitro in human AD brainsections. This technology may be used to detect plaques in vivo allowing earlydiagnosis of the disease and therapeutic intervention before cognitive declineoccurs.

ConditionOf Storage: -20± 5 °C

★ 本产品仅供研发使用，不能用于人体